scholarly journals Mechanism of allosteric inhibition in the Plasmodium falciparum cGMP-dependent protein kinase

2020 ◽  
Vol 295 (25) ◽  
pp. 8480-8491 ◽  
Author(s):  
Jung Ah Byun ◽  
Katherine Van ◽  
Jinfeng Huang ◽  
Philipp Henning ◽  
Eugen Franz ◽  
...  

Most malaria deaths are caused by the protozoan parasite Plasmodium falciparum. Its life cycle is regulated by a cGMP-dependent protein kinase (PfPKG), whose inhibition is a promising antimalaria strategy. Allosteric kinase inhibitors, such as cGMP analogs, offer enhanced selectivity relative to competitive kinase inhibitors. However, the mechanisms underlying allosteric PfPKG inhibition are incompletely understood. Here, we show that 8-NBD-cGMP is an effective PfPKG antagonist. Using comparative NMR analyses of a key regulatory domain, PfD, in its apo, cGMP-bound, and cGMP analog–bound states, we elucidated its inhibition mechanism of action. Using NMR chemical shift analyses, molecular dynamics simulations, and site-directed mutagenesis, we show that 8-NBD-cGMP inhibits PfPKG not simply by reverting a two-state active versus inactive equilibrium, but by sampling also a distinct inactive “mixed” intermediate. Surface plasmon resonance indicates that the ability to stabilize a mixed intermediate provides a means to effectively inhibit PfPKG, without losing affinity for the cGMP analog. Our proposed model may facilitate the rational design of PfPKG-selective inhibitors for improved management of malaria.

2020 ◽  
Vol 118 (3) ◽  
pp. 522a
Author(s):  
Olivia Byun ◽  
Katherine Van ◽  
Philipp Henning ◽  
Friedrich W. Herberg ◽  
Giuseppe Melacini

2013 ◽  
Vol 6 (2) ◽  
pp. 269-286 ◽  
Author(s):  
Stefanie Wolfertstetter ◽  
Johannes Huettner ◽  
Jens Schlossmann

2015 ◽  
Vol 16 (S1) ◽  
Author(s):  
Eugen Franz ◽  
Jeong Joo Kim ◽  
Olga Schneider ◽  
Daniela Bertinetti ◽  
Choel Kim ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e48206 ◽  
Author(s):  
Christine S. Hopp ◽  
Christian Flueck ◽  
Lev Solyakov ◽  
Andrew Tobin ◽  
David A. Baker

2021 ◽  
Vol 11 ◽  
Author(s):  
David Rotella ◽  
John Siekierka ◽  
Purnima Bhanot

The primary effector of cGMP signaling in Plasmodium is the cGMP-dependent protein kinase (PKG). Work in human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei has provided biological validation of P. falciparum PKG (PfPKG) as a drug target for treating and/or protecting against malaria. PfPKG is essential in the asexual erythrocytic and sexual cycles as well as the pre-erythrocytic cycle. Medicinal chemistry efforts, both target-based and phenotype-based, have targeted PfPKG in the past few years. This review provides a brief overview of their results and challenges.


Sign in / Sign up

Export Citation Format

Share Document